LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

23.34 0.78

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

22.43

Max

23.31

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+91.3% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	23M 1.5B
Vorige openingsprijs	22.56
Vorige sluitingsprijs	23.34

Nieuwssentiment

By Acuity

50%

165 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 feb 2026, 22:31 UTC

Winsten

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Winsten

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Winsten

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Winsten

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Marktinformatie

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Marktinformatie

Winsten

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Marktinformatie

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Winsten

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Marktinformatie

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Winsten

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Winsten

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Winsten

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Winsten

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Winsten

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Winsten

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Winsten

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Marktinformatie

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Winsten

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Winsten

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Winsten

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Winsten

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Winsten

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Winsten

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

91.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 44 USD 91.3%

Hoogste 62 USD

Laagste 24 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

165 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.